Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of December 2021, with a specific reporting date of December 22, 2021. The document serves as a transaction notification regarding share allocations for Persons Discharging Managerial Responsibilities (PDMRs), specifically Non-Executive Directors, for the service period of October 1, 2021, to December 31, 2021.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific equity transactions.
| Instrument | Transaction Date | Price | Total Volume (Shares/ADSs) |
|---|---|---|---|
| Ordinary Shares (GBP) | 2021-12-20 | £16.14 | 4,317.690 |
| American Depositary Shares (USD) | 2021-12-20 | $43.53 | 3,027.265 |
Note: Volumes are aggregated totals from the individual transactions listed in the filing.
Material Changes
The filing reports no material changes to the company's financial position or operations. The only changes reported are the acquisition of notional shares and ADSs by Non-Executive Directors as part of their standard share allocation arrangements.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a regulatory disclosure of director shareholdings.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions are acquisitions of notional shares/ADSs under share allocation arrangements for Non-Executive Directors, not open market purchases or sales.
- Participants: Transactions involve Sir Jonathan Symonds, Mr Charles Bancroft, Mr Vindi Banga, Dr Anne Beal, Dr Vivienne Cox, Ms Lynn Elsenhans, Dr Laurie Glimcher, Dr Jesse Goodman, and Mr Urs Rohner.
- Valuation: The transactions were executed at a price of £16.14 per Ordinary Share and $43.53 per ADS on December 20, 2021.
- Scope: This filing does not reflect the company's Q4 or full-year 2021 financial results.